12:00 AM
 | 
Jun 24, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Access AccuTnl+3 troponin I assay regulatory update

Danaher's Beckman Coulter Inc. subsidiary said FDA granted 510(k) clearance for its Access AccuTnl+3 troponin I assay for use on its Access 2 immunoassay system to determine levels of cardiac troponin...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >